Breast cancer test gave Atossa a revenue boost in Q2

08/16/2013 | GenomeWeb Daily News (free registration)

Atossa Genetics posted $326,078 in revenue during the second quarter, up from $223,097 in the same period last year. The increase was fueled by sales of the company's ForeCYTE Breast Health Test, which stratifies patients' breast cancer risk based on mammary aspirate samples.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX